GET DAILY SIGNALSWhy Is Veracyte (VCYT) Stock Down -54.72% Today?
Key Takeaways
- Veracyte (VCYT) shares plunged 54.72% to $23.78 in morning trading, down from the prior session's close of $52.52.
- The primary catalyst was a guidance reset for its best-selling Decipher prostate cancer test, including a second consecutive quarterly volume shortfall.
- Management cut its outlook for annual incremental Decipher test volume to 12,000–15,000, down from roughly 20,000 previously, with 2027 anchored at 12,000.
- The selloff overshadowed otherwise solid third-quarter results, including 15% revenue growth, a swing to profitability, and a new $100 million share repurchase program.
- Analysts questioned whether the reset fully captures changing adoption patterns and rising competitive pressure.
- Traders are now watching for analyst rating revisions, competitive developments in prostate diagnostics, and any signs of stabilization in Decipher volume.
- For additional details on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are navigating volatile markets, explore Trending AI Robots.
Opening Summary
Veracyte, Inc. (VCYT), a South San Francisco-based molecular diagnostics company focused on cancer care, saw its stock crater in Thursday's session after resetting growth expectations for its flagship Decipher prostate genomic classifier. Shares tumbled 54.72% to $23.78, a sharp reversal from the prior close of $52.52. The move marks a decisive break below the stock's prior 52-week trading range and reflects a market reaction to weakening demand trends in a core franchise, rather than any broad-market disruption.
Decipher Volume Reset Drives the Selloff
The dominant catalyst behind the decline was a downward revision to the company's outlook for Decipher, its prostate cancer tissue test. Veracyte reported roughly 29,900 Decipher tests sold during the third quarter, missing its own expectations by about 1,000 tests and representing the second consecutive quarter of disappointing volume. Management subsequently lowered its projection for annual incremental Decipher volume to a range of 12,000 to 15,000, down from approximately 20,000 previously, and anchored its 2027 expectations at the low end.
That reset struck at the heart of the investment thesis for VCYT. Decipher has been a key growth engine, and a slower adoption curve combined with what management described as evolving competitive dynamics raised concerns that the deceleration may be structural rather than temporary. Analysts echoed this skepticism, with one noting that the selloff reflects doubt about whether the revised guidance fully captures changing adoption patterns and intensifying competition.
Solid Financials Overshadowed by Guidance
The severity of the stock's decline is notable because the underlying quarterly results were otherwise constructive. Total revenue rose roughly 15% year over year to $151.75 million, gross profit expanded, and the company swung to a net profit of approximately $31.5 million, or $0.38 per diluted share. The company also authorized a new $100 million share repurchase program, a signal of management's confidence in the long-term value of the business.
Elsewhere in the portfolio, the Afirma thyroid test delivered another strong quarter with about 19,000 tests sold, up 12% year over year. However, investors focused squarely on the Decipher trajectory, and the momentum in other franchises was not enough to offset concerns about the company's most prominent growth asset.
Market Context and Trading Activity
Trading activity was exceptionally heavy as investors repriced the stock. Volume surged well above typical daily turnover, consistent with institutional repositioning following the guidance revision. The move diverged sharply from the broader market and from the healthcare and diagnostics sector, indicating that the decline was company-specific rather than a function of general risk-off sentiment.
From a technical standpoint, the shares gapped down through multiple support levels, including the stock's prior 52-week low, and traded decisively below key moving averages. The breakdown negated a previously constructive chart pattern that had been forming in recent months, leaving the stock at levels not seen in over a year.
What Comes Next for VCYT
The path forward for VCYT hinges on whether Decipher volume can stabilize and whether the revised guidance proves sufficiently conservative. Investors will be watching for any updates on competitive activity in prostate diagnostics, progress in the company's digital pathology and artificial intelligence initiatives, and readouts from ongoing clinical studies designed to support Decipher adoption.
Additional focus areas include the U.S. launch of the Prosigna breast cancer test, the continued momentum of Afirma, and how management deploys the newly authorized buyback. Key risks include further competitive erosion, slower-than-expected adoption of newer tests, and the possibility of additional downward revisions if current trends persist.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to observe how algorithmic approaches adapt to shifting market regimes. Explore the page to discover which AI-driven strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VCYT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for VCYT turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 75 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +7.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for VCYT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.041) is normal, around the industry mean (66.911). P/E Ratio (36.472) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers, develops and commercializes molecular diagnostic solutions
Industry MedicalSpecialties
Advertisement